Study on How Genetic Risk Modifiers Affect Health Decisions in Men with BRCA12 Mutations at Risk for Prostate Cancer

What this Trial Is About

Researchers are studying how men with BRCA1 or BRCA2 genetic mutations respond to testing that evaluates additional genetic factors affecting prostate cancer risk. The goal is to understand how this genetic risk modifier testing influences decisions about prostate cancer screening and impacts participants thoughts and feelings about their health care. The study focuses on men aged 45 to 70 who carry these mutations but do not currently have prostate cancer. Participants will be offered genetic risk modifier testing using a cheek buccal swab, which can be done in person or at home with a mailed kit. They will complete a baseline survey and additional surveys about one week, six months, and twelve months after receiving their updated cancer risk assessment results. There is also an optional blood collection for research testing. The genetic risk modifier testing is clinical grade but not yet standard care and is only available through this research. Throughout the study, participants will complete various questionnaires assessing psychological and behavioral outcomes related to their genetic testing results. Researchers will track their intention to undergo prostate cancer screening six months after testing. The study spans over a year with follow-up assessments at specific intervals. The research team monitors participants responses to better understand decision-making and emotional reactions. The total study participation lasts at least twelve months after receiving the test results.

Study of How People Make Decisions About Prostate Cancer Risk